GNH USA

Europe — EMA

Mivacurium Kalceks

GNH USA supplies Mivacurium Kalceks (Mivacurium), a neuromuscular blocker for endotracheal intubation and muscle relaxation. Request a quote for supply.

Mivacurium

Request sourcing

1
Pack/s

What is Mivacurium?

Mivacurium, the active ingredient in Mivacurium Kalceks, is a non‑depolarizing neuromuscular blocker presented as a sterile injectable solution for intravenous use. It facilitates endotracheal intubation, provides skeletal muscle relaxation during surgical procedures, and is indicated for rapid sequence induction and as an adjunct to general anesthesia in adult patients.

GNH USA supplies Mivacurium Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring quality‑assured delivery and regulatory compliance. The company adheres to Good Distribution Practice, offers temperature‑controlled logistics, and supports regulatory documentation for importation.

What is Mivacurium used for?

Mivacurium is used in anesthesia to produce rapid, reversible skeletal muscle relaxation.

- Endotracheal intubation: provides rapid muscle relaxation to facilitate airway management. - Surgical muscle relaxation: enables controlled ventilation and optimal surgical conditions during procedures. - Adjunct to general anesthesia: enhances overall anesthetic depth and stability in adult patients.

What are the side effects of Mivacurium?

Mivacurium may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Flushing: transient skin reddening. - Tachycardia: increased heart rate. - Hypotension: mild blood pressure drop. - Nausea: occasional queasiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring emergency care. - Prolonged apnea: extended respiratory muscle paralysis needing ventilation support.

What precautions apply to Mivacurium?

When using Mivacurium, clinicians should observe specific safety measures.

- Patient assessment: evaluate neuromuscular function and baseline respiratory status before administration. - Dose adjustment: consider reduced dosing in patients with hepatic or renal impairment. - Allergy history: screen for hypersensitivity to mivacurium or related compounds. - Concurrent anesthesia: monitor depth of anesthesia and ensure adequate ventilation. - Pregnancy and lactation: use only if potential benefits justify potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mivacurium interact with?

Mivacurium can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - Lithium: can enhance the blocking effect. - Magnesium sulfate: may increase muscle relaxation duration.

Moderate Interactions (Monitor Closely): - Volatile anesthetics: additive effect on muscle relaxation. - Inhalational anesthetics: may prolong duration of action. - Beta‑adrenergic blockers: may affect cardiovascular response during blockade.

Frequently asked questions

What is Mivacurium Kalceks used for?+
Mivacurium Kalceks is employed in the peri‑operative setting to produce rapid, reversible skeletal muscle relaxation. It is primarily used to facilitate endotracheal intubation and to maintain muscle relaxation during surgical procedures, acting as an adjunct to general anesthesia in adult patients.
How does mivacurium work?+
Mivacurium works by competitively blocking nicotinic acetylcholine receptors at the motor end‑plate of skeletal muscle. This inhibition prevents acetylcholine‑mediated depolarization, stopping nerve impulse transmission and resulting in a dose‑dependent, reversible muscle relaxation.
What determines the dose of Mivacurium Kalceks?+
The appropriate dose of Mivacurium Kalceks is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the specific procedural requirements. Dosing guidelines are provided in the product label, but the final regimen is set by the treating physician.
Is Mivacurium safe in pregnancy or breastfeeding?+
Mivacurium is classified as pregnancy category unknown. It should be used during pregnancy or lactation only when the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians should assess the risk‑benefit ratio on an individual basis.
How do I order Mivacurium Kalceks from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.
How does Mivacurium compare with other neuromuscular blockers?+
Mivacurium is a short‑acting, non‑depolarizing blocker that is rapidly hydrolyzed by plasma cholinesterases, leading to a quicker recovery compared with agents such as rocuronium or vecuronium. Its rapid offset makes it useful for brief procedures, whereas longer‑acting agents are preferred when prolonged muscle relaxation is needed.
What are the storage and handling requirements for Mivacurium Kalceks?+
Mivacurium Kalceks should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if the container is damaged or if the solution appears discolored.
How is Mivacurium administered?+
Mivacurium is administered by intravenous injection. The clinician injects the prepared sterile solution directly into a vein, usually as a bolus dose followed by a continuous infusion if prolonged relaxation is required. Administration is performed under close monitoring of neuromuscular function and vital signs.
What are the most serious risks associated with Mivacurium?+
The most serious adverse events include anaphylaxis, which can be life‑threatening and requires immediate emergency treatment, and prolonged apnea, where respiratory muscle paralysis persists longer than expected, necessitating assisted ventilation. Severe hypotension and cardiac arrhythmias are also rare but critical complications.
Who should not use Mivacurium?+
Mivacurium should be avoided in patients with a known hypersensitivity to the drug or to other non‑depolarizing neuromuscular blockers. Caution is advised in individuals with severe hepatic or renal impairment, as well as in patients with conditions that predispose them to malignant hyperthermia or significant cardiovascular instability.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mivacurium
Route
Intravenous Use
Manufacturer
Kalceks
Origin
EU

Related products

Mivacron

Mivacron

Mivacurium

Aspen Pharma Trading Limited
EU
Mivacron

Mivacron

Mivacurium

Aspen Pharma Trading Limited
EU
Mivacron

Mivacron

Mivacurium

Aspen Pharma Trading Limited
EU
Mivacron

Mivacron

Mivacurium

Aspen Pharma Trading Limited
EU